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SUMMARY. We present a case of fetal and neonatal alloimmune thrombocytopenia (FNAT) in secundipara woman. In her 
fi rst pregnancy, she delivered a newborn with a heavy form of neonatal autoimmune thrombocytopenia. The diagnosis 
was confi rmed by the evidence of anti HPA-1a antibodies in HPA-1a negative mother and a positive homozygous 
HPA-1a father. The newborn was treated with platelet transfusions (PT) and corticosteroid therapy because of a devel-
oped widespread skin petechiae and markedly low platelet count (19 × 109). According to the outcome of the fi rst preg-
nancy in the index pregnancy the therapeutic regime consisted of a weekly administration of intravenous immunoglobu-
lin (IVIG) in 1mg/kg of mother weight dose from week 20 until week 36. There were no maternal or fetal complications 
throughout pregnancy and a vital, female newborn 3720 g. was delivered by elective Caesarean section in the 37 weeks 
of gestation. The newborn had no clinical signs of FNAT, and there was normal platelet count of 146 × 109/L and nega-
tive test for antithrombocytic IgG antibodies in umbilical cord blood. We concluded that the therapy regime was optimal 
because of the lack of clinical signs of disease as well as normal laboratory fi ndings. Due to low incidence and specifi c 
antenatal diagnostic protocol and treatment, it is recommended to present and collect cases of FNAT.
Introduction
Fetal and neonatal alloimmune thrombocytopenia 
(FNAT) is a disease caused by maternal production of 
an antibody-mediated immunological response against 
a platelet-specifi c antigen, present on the fetal platelets 
and inherited from the father. Maternal IgG alloantibod-
ies form antigen-antibody complex that lead to fetal 
platelet destruction. There are several human platelet 
antigens that play crucial role in FNAT pathogenesis, 
from which HPA-1a and HPA-5b are the most frequent. 
The incidence ranges from 1:1000 to 1:2000 and main 
diagnostic criteria is platelet count lower than 
150×109/L.1
In severe form of this disease platelet count is lower 
than 50×109/L. As opposite to RhD immunization, it is 
typical that fetus could be affected in the fi rst pregnan-
cy. There are few clinical presentations, ranging from 
asymptomatic to pathognomonic form, like intracranial 
hemorrhage (ICH) which can lead to severe neurologic 
damage or even to the lethal outcome.2,3 Also, there are 
a few frequent extracranial manifestations of FNAT: 
gastrointestinal bleeding, as well as bleeding in lungs, 
kidneys, eyes, spinal canal etc.4
Today, in most clinical centers, intravenous immuno-
globulins (IVIG) are the fi rst-line therapy, but therapeu-
tical protocols regarding dosage and duration are not 
yet established and confi rmed. There is a lack of con-
trolled randomised trials due to the low incidence of 
FNAT. Therapeutic protocols are mostly derived from 
case reports and small series. In this report, we present 
a successful treatment of FNAT in secundipara who de-
livered in her fi rst pregnancy newborn with a heavy 
form of neonatal autoimmune thrombocytopenia.
Case report
A 32-year-old secundipara gave normal, vaginal birth 
to her fi rst child 3 years ago, at 37 weeks of uncompli-
cated pregnancy. A male newborn birthweight 3120 g, 
with normal Apgar scores, was transported to a tertiary 
center a few hours after birth because of a widespread 
skin petechial hemorrhages. The laboratory fi ndings 
showed a very severe thrombocytopenia ranging 19–24 
× 109/L. The mother was found to be HPA-1a negative, 
the child was HPA-1a positive and the diagnosis of 
FNAT was confi rmed by maternal HPA-1a alloantibod-
ies. The father was homozygous positive HPA-1a/a. 
The therapy consisted of platelet transfusions and corti-
costeroids.
The child was discharged in good condition on the 
19th postpartal day. In the index pregnancy, maternal 
HPA-1a alloantibody titer was 1:64 in the 10th week, 
and 1:16 in the 29th week of gestation. The therapy con-
sisted of a weekly IVIG administration in doses of 1g/
kg of mother s weight starting from 20th week until 
35+3/7 week. Routine maternal laboratory fi ndings were 
normal and no therapy side effects were noticed. Fetal 
morphology, growth, biophysical profi les and Doppler 
measurements were normal and there were no ultra-
sound fi ndings indicating intracranial hemorrhage 
(ICH). At 36+6/7 weeks of gestation a female new-
born was delivered by elective cesarean section, birth-
weight 3720 g, and normal Apgar scores. In umbilical 
cord blood the platelet count was 146 × 109/L, and 120 
× 109/L in the peripheral blood and no IgG antithrom-
bocytic alloantibodies were found. Healthy child was 
discharged in early neonatal period from our depart-
ment.
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Discussion
Fetal and neonatal alloimmune thrombocytopenia is 
mainly diagnosed in pregnant women who had given 
birth to an affected child. Diagnosis is rarely made in 
the fi rst pregnancy when intra or extracranial hemor-
rhage is detected on ultrasound or there is anamnestic 
data about FNAT in sisters or close family members. 
Nevertheless, in most Western countries apart from 
Norway and Denmark, the FNAT screening program is 
not implemented because of high cost and low inci-
dence of the disease.5 In our case, the outcome of the 
fi rst pregnancy was an indication for the FNAT testing 
and the diagnosis was confi rmed by maternal antiplate-
let HPA-1a antibodies and paternal HPA-1a/a homozy-
gosity. If the father is heterozygous HPA-1a/b then there 
is a 50% chance that the fetus is HPA-1bb. In that case, 
amniocentesis is indicated for fetal genotype testing. If 
the fetal genotype is HPA-1bb, the condition can be ex-
cluded because it is identical to the mother’s genotype. 
Some countries have recently implemented HPA typing 
of free fetal DNA isolated from maternal blood.5
About thirty years ago FNAT was exclusively treated 
by intrauterine platelet transfusions (IPT). The lack of 
such therapeutic approach is weekly repetitions due to 
short half-life of transfused platelets and severe compli-
cations like bradycardia, prolonged insertion bleeding 
or cord thrombosis.3,6,7 The risk of fetal loss or an emer-
gency premature Caesarean section after IPT is 11%.8 
Bussel and al. introduced IVIG to achieve the same 
therapeutic effect and to avoid procedure-related com-
plications.9 Therapy is being implemented based on re-
ports of benefi cial effects of maternal administration of 
IVIG in pregnancies with immune thrombocytopenia. 
The basic principle of IVIG treatment is prevention of 
thrombocytopenia-related bleeding complications, 
however, the working mechanism of IVIG is still not 
clear and remains subject of research. Most likely, it 
acts on various levels, most important of which are the 
stabilisation of blood vessels endothelium and the inter-
ference HPA antibody transduction.10,11 If there is no 
treatment, risk of fetal bleeding in index pregnancy in 
women with previous fetal ICH is 79%.12 Over the last 
two decades IVIG therapy has almost completely re-
placed the IPT with a nearly 100% success rate of fetal 
bleeding prevention.2,13–16 Cochran’s analysis and recent 
systematic review of 27 studies have shown that IVIG 
therapy reduces the risk of ICH by 97,3% or even 
98,7%.17,8 Some authors combine IVIG therapy with 
steroids, however, randomised studies reported no sig-
nifi cant difference on fetal loss, ICH frequency or neo-
natal platelet count.18 Dosage of IVIG and length of 
therapy is based on anamnestic data of ICH in the previ-
ous pregnancy. Generally, high-risk pregnancies should 
be treated with higher dose of IVIG and an earlier onset 
of IVIG administration compared to low-risk pregnan-
cies.
There is no consensus regarding the doses and length 
of IVIG treatment. The recommendations are different 
and doses vary from 0,5 to 2,0 g/kg of the mother’s 
body weight/per week. The Dutch group recently rec-
ommended weekly doses of IVIG of 1,0 g/kg for high-
risk pregnancies started from 12th to 16th week and con-
tinued until the 36th week when delivery should be 
planned.19 For low-risk pregnancies weekly doses of 
IVIG consist of 0,5 g/kg from 24 to 37 weeks. In both 
cases, ultrasound exam of fetal brain should be per-
formed every two to four weeks. Winkelhorst et al. 
draw attention to the risk of extracranial hemorrhage 
during pregnancy and authors described gastrointestinal 
bleeding, as well as bleeding in spinal canal, lungs, kid-
neys, eyes etc.4 Norwegian authors indicate and moder-
ate therapy according to the maternal anti-HPA 1a anti-
body level. They reported the sensitivity of over 90% in 
predicting severe neonatal thrombocytopenia.5,20 This 
concept does not apply in other countries with arguing 
that the level and dynamics of the antibody does not 
correlate to the severity of FNAT.21–23 Moreover, cases 
with severe fetal bleeding and minimal maternal anti-
HPA-1a antibody concentrations have been reported.21
In this case, we considered that there was a high risk 
of hemorrhage due to severe thrombocytopenia and ex-
tensive petechial bleeding in the sibling. Therefore, the 
doses of IVIG and length of therapy have been applied 
for a high-risk pregnancy. The therapy strategy was not 
changed due to normal ultrasound fi ndings of the fetus 
and mother’s favorable tolerance to the medication. Al-
though the level of HPA-1a antibodies are not reliable 
for the monitoring the therapeutic effect, we concluded 
that the titre drop from 1:64 in the 10th week at 1:16 in 
the 29th week indirectly indicated a good therapeutic ef-
fect. This fi nding correlated with the umbilical cord 
platelets count (146×109/L) after birth and negative 
fi ndings of a direct test of antiplatelet IgG antibodies 
and antiplatelet antibodies determined by the immuno-
fl uorescence method. There is no consensus of how to 
deliver pregnant women with FNAT, although smaller 
cohort studies have not shown that vaginal delivery in-
creases the risk of ICH. In low-risk cases, vaginal deliv-
ery is preferred around the 38th week.19,24 3 Due to risk of 
fetal bleeding, any trauma such as assisted delivery the 
use of a scalp electrode or collecting blood from the 
fetus should be avoided during delivery. Most centers 
recommend Cesarean section between the 36th and 38th 
weeks of gestation, if there was ICH in the previous 
pregnancy.3,19 Some centers use cordocentesis to verify 
therapeutic effect and to choose the mode of delivery. In 
our case Cesarean section was performed because the 
mother did not accept any risk of vaginal delivery even 
with the risk of possible cordocentesis. According to the 
platelet count from umbilical cord after delivery 
(146×109/L) it can be concluded that birth could have 
been performed vaginally.
A study that analyzed the period from 2009 to 2013 
has revealed that 52 newborns in Croatia were diag-
nosed with FNAT.25 The analysis was possible for 38 
newborns and the results showed that none of newborns 
had ICH. No symptoms showed 20 newborns (53%), 16 
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had petechiae (42%) and 2 had gastrointestinal bleeding 
(5%). The average platelet count was 50×109/L (min 5, 
max 107). The treatment was not required for 29 new-
borns (76%) and others were treated with platelet trans-
fusions, immunoglobulins and corticosteroids. Accord-
ing to the total number of births in Croatia in that period 
the incidence of FNAT is 1:4000 births. By exploring 
Croatian medical data, we have not been able to access 
the data on the numbers and treatment methods of preg-
nant women with FNAT in the previous pregnancy.
In this case, since there were no clinical or laboratory 
fi ndings of FNAT in the newborn it can be concluded 
that prenatal therapy was successful. Normal neonatal 
platelet count and non-detectable antiplatelet IgG anti-
bodies indicate that the duration of therapy and therapy 
doses were optimal.
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Ključne riječi:  fetalna i neonatalna aloimuna trombocitopenija, antitrombocitna antitijela, HPA-1a, 
intravenski imunoglobulini
SAŽETAK. U prikazu slučaja je opisan dijagnostički postupak i uspješno liječenje fetoneonatalne aloimune trombocito-
penije (FNAT) kod trudnice koja je u prethodnoj trudnoći rodila dijete sa teškim oblikom ove bolesti. Dijagnoza FNAT 
postavljena je postnatalno dokazom anti-HPA-1a antitrombocitnih protutijela kod HPA-1a negativne majke i oca koji je 
bio HPA-1a /a pozitivan homozigot. Novorođenče je zbog izraženih petehijalnih krvarenja i teške trombocitopenije (19 
× 109/L) liječeno transfuzijama trombocita i kortikosteroidima. U ovoj trudnoći je, s obzirom na ishod prethodne 
trudnoće, indicirano liječenje intravenskim imunoglobulinima (IVIG). Liječenje je trajalo od 20. do 35. tjedna jedanput 
tjedno u dozi 1 g /kg tjelesne težine majke. Trudnoća je protekla bez fetalnih i majčinskih komplikacija, a elektivnim 
carskim rezom je u 36. tjednu porođeno žensko vitalno dijete 3720 g. Izostanak kliničkih simptoma FNAT te uredan 
nalaz trombocita iz pupkovine (146 × 109/L) i negativan direktni test na antitrombocitna protutijela IgG i imunofl uore-
scentna antitrombocitna protutijela ukazuju na optimalan terapijski učinak s IVIG. S obzirom da FNAT u dijagnostičkom 
i terapijskom smislu ne spada u kliničku rutinu korisno je objavljivanje i prikupljanje pojedinačnih slučajeva ove rijetke 
bolesti.
